Renal cell carcinoma (RCC) is a major metabolic cancer, and several well-known renal cancer genes are involved in pathways that respond to metabolic stress. Thus, there is a critical need to understand the metabolic stress pathways involved in RCC development and to develop treatments that target the fundamental metabolic vulnerabilities in RCC. BAP1 acts as a tumor suppressor gene in RCC, with inactivating mutations in up to 15% of cases and frequent deletion in clear cell RCCs (ccRCCs), and patients with BAP1-mutant ccRCC exhibit particularly poor clinical outcomes. However, how BAP1 functions as a tumor suppressor in renal cancer remains unclear, and currently there is no effective therapy to treat RCC patients with BAP1 mutations. BAP1 and its associated proteins form the polycomb repressive deubiquitinase (PR-DUB) complex, which reduces histone 2A ubiquitination (H2Aub) on chromatin and regulates gene transcription. SLC7A11 is a cystine transporter. Our recent publications and preliminary data link BAP1 to SLC7A11 and support the central hypotheses of our proposal that (i) the BAP1-containing PR-DUB complex mediates H2Aub de-ubiquitination and transcriptional repression of SLC7A11, and BAP1 deficiency or alteration of other components in the PR-DUB complex de- represses SLC7A11 expression, rendering renal cancer cells more resistant to ferroptosis (a non-apoptotic cell death induced by metabolic stress) and contributing to RCC development; and (ii) BAP1-deficient/mutant renal tumors are more dependent on glucose for survival, partly due to high SLC7A11 expression in these tumors, thus exposing a metabolic vulnerability for therapeutic targeting. In this proposal, we will employ multi-disciplinary approaches to test our hypotheses. The rationale for the proposed research is that studying the roles of the BAP1-SLC7A11 signaling axis in ferroptosis and glucose dependency will not only advance our understanding of how renal cancer cells bypass ferroptotic cell death to survive and grow but also provide important insights into the development of novel therapeutic strategies to target accompanying metabolic vulnerabilities in RCC. With respect to expected outcomes, our proposed studies will identify novel regulatory mechanisms of ferroptosis pathways, clarify the tumor suppression function of BAP1, and identify new effective therapies to target metabolic vulnerabilities in renal cancer. Our proposal is highly innovative because it focuses on a previously unexplored pathway to link metabolic stress signaling to tumor development and treatment. Our proposed studies will have significant impact on both our understanding of the fundamental mechanisms of metabolic stress response and our ability to target nutrient dependency in renal cancer treatment.

Public Health Relevance

There is a critical need to understand the metabolic stress pathways involved in renal cell carcinoma (RCC) development and to develop treatments that target the fundamental metabolic vulnerabilities in RCC. The objective of this application is to study the roles and mechanisms of the RCC tumor suppressor BAP1 in the regulation of ferroptosis and glucose dependency, and the relevance of this regulation to renal tumor development and treatment. Our proposed studies will have significant impact on both our understanding of the fundamental mechanisms of metabolic stress response and our ability to target nutrient dependency in renal cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA181196-07A1
Application #
9971284
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Salnikow, Konstantin
Project Start
2014-06-01
Project End
2025-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Radiation-Diagnostic/Oncology
Type
Hospitals
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Koppula, Pranavi; Zhang, Yilei; Zhuang, Li et al. (2018) Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond) 38:12
Kim, Jongchan; Piao, Hai-Long; Kim, Beom-Jun et al. (2018) Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet 50:1705-1715
Chauhan, Anoop Singh; Liu, Xiaoguang; Jing, Ji et al. (2018) STIM2 interacts with AMPK and regulates calcium-induced AMPK activation. FASEB J :fj201801225R
Yadav, Raj Kumar; Chauhan, Anoop Singh; Zhuang, Li et al. (2018) FoxO transcription factors in cancer metabolism. Semin Cancer Biol 50:65-76
Zhang, Yilei; Shi, Jiejun; Liu, Xiaoguang et al. (2018) BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 20:1181-1192
Xiao, Zhen-Dong; Han, Leng; Lee, Hyemin et al. (2017) Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. Nat Commun 8:783
Dai, Fangyan; Lee, Hyemin; Zhang, Yilei et al. (2017) BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response. Proc Natl Acad Sci U S A 114:3192-3197
Koppula, Pranavi; Zhang, Yilei; Shi, Jiejun et al. (2017) The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem 292:14240-14249
Lee, Hyemin; Dai, Fangyan; Zhuang, Li et al. (2016) BAF180 regulates cellular senescence and hematopoietic stem cell homeostasis through p21. Oncotarget 7:19134-46
Xiao, Zhen-Dong; Zhuang, Li; Gan, Boyi (2016) Long non-coding RNAs in cancer metabolism. Bioessays 38:991-6

Showing the most recent 10 out of 18 publications